Literature DB >> 16291886

Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up.

W M M Schüpbach1, N Chastan, M L Welter, J L Houeto, V Mesnage, A M Bonnet, V Czernecki, D Maltête, A Hartmann, L Mallet, B Pidoux, D Dormont, S Navarro, P Cornu, A Mallet, Y Agid.   

Abstract

BACKGROUND: The short term benefits of bilateral stimulation of the subthalamic nucleus (STN) in patients with advanced levodopa responsive Parkinson's disease (PD) are well documented, but long term benefits are still uncertain.
OBJECTIVES: This study provides a 5 year follow up of PD patients treated with stimulation of the STN.
METHODS: Thirty seven consecutive patients with PD treated with bilateral STN stimulation were assessed prospectively 6, 24, and 60 months after neurosurgery. Parkinsonian motor disability was evaluated with and without levodopa treatment, with and without bilateral STN stimulation. Neuropsychological and mood assessments included the Mattis Dementia Rating Scale, the frontal score, and the Montgomery-Asberg Depression Rating Scale (MADRS).
RESULTS: No severe peri- or immediate postoperative side effects were observed. Six patients died and one was lost to follow up. Five years after neurosurgery: (i) activity of daily living (Unified Parkinson Disease Rating Scale (UPDRS) II) was improved by stimulation of the STN by 40% ("off" drug) and 60% ("on" drug); (ii) parkinsonian motor disability (UPDRS III) was improved by 54% ("off" drug) and 73% ("on" drug); (iii) the severity of levodopa related motor complications was decreased by 67% and the levodopa daily doses were reduced by 58%. The MADRS was unchanged, but cognitive performance declined significantly. Persisting adverse effects included eyelid opening apraxia, weight gain, addiction to levodopa treatment, hypomania and disinhibition, depression, dysarthria, dyskinesias, and apathy.
CONCLUSIONS: Despite moderate motor and cognitive decline, probably due to disease progression, the marked improvement in motor function observed postoperatively was sustained 5 years after neurosurgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291886      PMCID: PMC1739461          DOI: 10.1136/jnnp.2005.063206

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  27 in total

1.  Body weight gain rate in patients with Parkinson's disease and deep brain stimulation.

Authors:  Michela Barichella; Agnieszka M Marczewska; Claudio Mariani; Andrea Landi; Antonella Vairo; Gianni Pezzoli
Journal:  Mov Disord       Date:  2003-11       Impact factor: 10.338

2.  HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI.

Authors:  P P RICKHAM
Journal:  Br Med J       Date:  1964-07-18

3.  What contributes to quality of life in patients with Parkinson's disease?

Authors:  A Schrag; M Jahanshahi; N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

4.  Effect of bilateral subthalamic electrical stimulation in Parkinson's disease.

Authors:  G Broggi; A Franzini; P Ferroli; D Servello; L D'Incerti; S Genitrini; P Soliveri; F Girotti; T Caraceni
Journal:  Surg Neurol       Date:  2001-08

5.  Behavioural disorders, Parkinson's disease and subthalamic stimulation.

Authors:  J L Houeto; V Mesnage; L Mallet; B Pillon; M Gargiulo; S Tezenas du Moncel; A M Bonnet; B Pidoux; D Dormont; P Cornu; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

6.  Clinical predictive factors of subthalamic stimulation in Parkinson's disease.

Authors:  M L Welter; J L Houeto; S Tezenas du Montcel; V Mesnage; A M Bonnet; B Pillon; I Arnulf; B Pidoux; D Dormont; P Cornu; Y Agid
Journal:  Brain       Date:  2002-03       Impact factor: 13.501

7.  Subthalamic stimulation in Parkinson disease: intraoperative predictive factors.

Authors:  Jean-Luc Houeto; Marie-Laure Welter; Paul-Boulos Bejjani; Sophie Tezenas du Montcel; Anne-Marie Bonnet; Valerie Mesnage; Soledad Navarro; Bernard Pidoux; Didier Dormont; Philippe Cornu; Yves Agid
Journal:  Arch Neurol       Date:  2003-05

8.  Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.

Authors:  Paul Krack; Alina Batir; Nadège Van Blercom; Stephan Chabardes; Valérie Fraix; Claire Ardouin; Adnan Koudsie; Patricia Dowsey Limousin; Abdelhamid Benazzouz; Jean François LeBas; Alim-Louis Benabid; Pierre Pollak
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245

9.  How do parkinsonian signs return after discontinuation of subthalamic DBS?

Authors:  P Temperli; J Ghika; J-G Villemure; P R Burkhard; J Bogousslavsky; F J G Vingerhoets
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

10.  Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease.

Authors:  Galit Kleiner-Fisman; David N Fisman; Elspeth Sime; Jean A Saint-Cyr; Andres M Lozano; Anthony E Lang
Journal:  J Neurosurg       Date:  2003-09       Impact factor: 5.115

View more
  100 in total

1.  Parkinson disease: deep brain stimulation versus best medical therapy for PD.

Authors:  Matthew A Brodsky; John G Nutt
Journal:  Nat Rev Neurol       Date:  2010-10       Impact factor: 42.937

2.  A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD.

Authors:  R J St George; J G Nutt; K J Burchiel; F B Horak
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

3.  Chronic high-frequency stimulation therapy in hemiparkinsonian rhesus monkeys using an implanted human DBS system.

Authors:  Yiqun Cao; Peihao Yin; Xiaowu Hu; Yiqin Ge; Xiaoping Zhou
Journal:  Neurol Sci       Date:  2012-05-24       Impact factor: 3.307

4.  Motor follow-up of parkinsonian patients after deep-brain stimulation.

Authors:  Giovanni Caranci; Francesco Lena; Nicola Modugno; Stefano Ruggieri; Pantaleo Romanelli; Mario Manfredi
Journal:  Neurol Sci       Date:  2010-07-22       Impact factor: 3.307

Review 5.  [Deep brain stimulation for Parkinson's disease].

Authors:  J Herzog; G Deuschl
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

6.  Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes.

Authors:  Frances M Weaver; Kenneth A Follett; Matthew Stern; Ping Luo; Crystal L Harris; Kwan Hur; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda
Journal:  Neurology       Date:  2012-06-20       Impact factor: 9.910

Review 7.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

8.  Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases.

Authors:  Angelo Franzini; Roberto Cordella; Giuseppe Messina; Carlo Efisio Marras; Luigi Michele Romito; Alberto Albanese; Michele Rizzi; Nardo Nardocci; Giovanna Zorzi; Edvin Zekaj; Flavio Villani; Massimo Leone; Orsola Gambini; Giovanni Broggi
Journal:  Neurol Sci       Date:  2012-01-24       Impact factor: 3.307

Review 9.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Are there adaptive changes in the human brain of patients with Parkinson's disease treated with long-term deep brain stimulation of the subthalamic nucleus? A 4-year follow-up study with regional cerebral blood flow SPECT.

Authors:  Stelvio Sestini; Alberto Pupi; Franco Ammannati; Ramat Silvia; Sandro Sorbi; Antonio Castagnoli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.